Onyx’s Transformative Year: From Productive Partner To Big Cap Contender?
Executive Summary
Onyx Pharmaceuticals is working to execute on two launches and produce late-stage data that will enable it to add more indications to its growing roster of marketed drugs. If it succeeds, it could eventually rival competitor Celgene as one of the few biotechs to move from a small cap into the big cap ranks, but any stumbles could slow or eliminate Onyx’s evolution.
You may also be interested in...
After ASH, Amgen Assuages Wall Street Over Kyprolis CV Concerns
The biotech took time to address the recent suspicion that there are more cardiovascular events than previously expected with Kyprolis. But the bottom line is that head-to-head efficacy and safety data against Velcade, another multiple myeloma proteasome inhibitor, simply aren’t available yet.
As Onyx Details Come Out, Amgen Turns To Biosimilars
Amgen is juggling both ends of its strategy, one focused on biosimilars and the other on new R&D-driven products. Further details have emerged about each, as Amgen tries to make the case it's a revenue growth story.
Amgen Wins Onyx, But Will The Deal Pave The Road To Transformation?
The addition of Onyx’s cancer drugs to Amgen’s portfolio will fill a near-term sales gap for the big biotech and reinforce the company as a major oncology player. But Amgen will need to execute expertly on the merger if it is to transform itself into a high-growth biotech.